NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
M.D. Anderson Cancer Center
Leo W. Jenkins Cancer Center
National Cancer Institute (NCI)
Western Regional Medical Center
New Mexico Cancer Research Alliance
New Mexico Cancer Research Alliance
Kentuckiana Cancer Institute